Clinical efficacy and safety study of Shenbai lotion in the treatment of mild to moderate seborrheic dermatitis on the scalp

Guangzhou Institute of Dermatology0 个研究点开始时间: 待定最近更新: 2023年10月16日

适应症

试验速览

暂无简介。

•1\Subjects aged 18 to 60 years (including 18 and 60 years old) diagnosed with mild to moderate seborrheic dermatitis of the scalp, regardless of gender\2\Subjects recieved no systemic or local application of antibiotics, antifungal drugs, corticosteroids, or other drugs for the treatment of seborrheic dermatitis within 4 weeks;3\There is no severe hair loss, with hair growth covering at least 70% of the scalp;4\The participants should sign an informed consent and comply with medical advice.

•1\Subjects have used systemic or local antibiotics, antifungal drugs, corticosteroids, and other drugs to treat seborrheic dermatitis in the past 4 weeks;2\Scalp has co-exist with other conditions;3\Those who suffering from serious systemic diseases, which may affect the evaluators of the results, such as autoimmune diseases, arrhythmia, liver and kidney diseases, blood system diseases, malignant tumors, chronic severe infections, diabetes, psychosis;4\Those who have participated or are currently participating in other clinical trials within 3 months;5\Having pegnancy, lactation, or planned pregnancy during the study period;6\Individuals who are known to be allergic to the ingredients of this medicine;7\Subjects is not possible to give full informed consent due to mental and behavioral disorders;8\Subjects should be exclued according to the researcher's judgment, such as frequent changes in the work environment and other pathological changes that reduce the likelihood of enrollment or complicate enrollment, which may easily lead to loss of follow-up.

发起方

Guangzhou Institute of Dermatology